Turn Therapeutics Files $150M Shelf and Launches $50M TD Cowen ATM
TTRX has more than doubled off its 52-week low of $2.57.
Summary
Turn Therapeutics registered a $150 million shelf and a $50 million at-the-market stock program with TD Cowen. No shares have been sold; the company gains a standing ability to raise cash, at the price of dilution when it draws.
Key Events · Financing and Capital Events · TTRX
-
$150M Shelf Plus $50M ATM Registered
The S-3 registers up to $150,000,000 of common stock, preferred stock, debt securities, warrants, rights and units, alongside a $50,000,000 sales agreement prospectus for common stock sold through TD Cowen.
-
No Shares Sold Yet
This filing registers capacity only; no proceeds reach the company until it delivers placement notices and shares are actually sold under the sales agreement.
-
Dilution Math at Current Price
At the $9.48 last reported sale price on November 6, 2026, the full $50,000,000 ATM equals about 5,274,262 shares — roughly 17% of the 30,572,704 shares outstanding.
-
Agent Fees and Expenses
TD Cowen receives up to 3.0% of gross proceeds plus reimbursement of up to $100,000 of its legal expenses; total offering expenses excluding commissions are estimated at about $300,000.
Analysis · TTRX · Life Sciences
The lifeline here is capacity, not cash: Turn Therapeutics can now sell up to $150 million of securities over time, including up to $50 million of common stock through TD Cowen at market prices. No shares have been sold yet, so this is a standing ability to raise, not a completed raise. For a clinical-stage biotech carrying a going-concern warning and $10.4 million of cash, that drip-feed equity option is the main funding backstop — and the cost is dilution on every drawdown. At the $9.48 last sale price, the full $50 million ATM would be roughly 5.27 million shares, or about 17% of the 30.57 million shares outstanding, and that sits on top of the 25.4 million shares registered for resale in the companion S-3 filed today.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TTRX was trading at $9.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $289.5M. The 52-week trading range was $2.57 to $16.45. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.